Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development: Figure 1.

FDA Perspective on Companion Diagnostics: An Evolving Paradigm

(2014) E. A. Mansfield   CLINICAL CANCER RESEARCH

Personalizing Oncology: Perspectives and Prospects

(2013) John Mendelsohn   JOURNAL OF CLINICAL ONCOLOGY

Precision Oncology: An Overview

(2013) Levi A. Garraway et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

(2010) L. Seymour et al.   CLINICAL CANCER RESEARCH

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

(2009) S Postel-Vinay et al.   BRITISH JOURNAL OF CANCER

Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology

(2009) Ultan McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY